CSL Behring to Contest U.S. Block on $3.1 Billion Talecris Biotherapeutics Deal
Reuters -- Australian blood products group CSL Ltd said on Thursday it will fight a U.S. regulator's move to block a planned $3.1 billion takeover of smaller U.S. rival Talecris Biotherapeutics Holdings Corp.